 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
2 News |  |
- | L1-10 / Amgen, Opdivo (nivolumab) / BMS
Enrollment open, PD(L)-1 Biomarker: Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% (clinicaltrials.gov) - Mar 21, 2019
P2, N=22, Recruiting, Sponsor: National Cancer Center, Korea
Not yet recruiting --> Recruiting
- | L1-10 / Amgen, Opdivo (nivolumab) / BMS
New P2 trial, PD(L)-1 Biomarker: Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% (clinicaltrials.gov) - Jan 16, 2019
P2, N=22, Not yet recruiting, Sponsor: National Cancer Center, Korea